News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
775,219 Results
Type
Article (54036)
Company Profile (336)
Press Release (720830)
Multimedia
Podcasts (161)
Webinars (25)
Section
Business (216680)
Career Advice (3077)
Deals (37676)
Drug Delivery (146)
Drug Development (86278)
Employer Resources (191)
FDA (17437)
Job Trends (16134)
News (369002)
Policy (35981)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2880)
Accelerated approval (40)
Adcomms (35)
Allergies (163)
Alliances (54161)
ALS (189)
Alzheimer's disease (1772)
Antibody-drug conjugate (ADC) (372)
Approvals (17658)
Artificial intelligence (615)
Autoimmune disease (201)
Automation (47)
Bankruptcy (387)
Best Places to Work (12184)
BIOSECURE Act (23)
Biosimilars (209)
Biotechnology (198)
Bladder cancer (173)
Brain cancer (68)
Breast cancer (682)
Cancer (5272)
Cardiovascular disease (467)
Career advice (2602)
Career pathing (44)
CAR-T (307)
CDC (64)
Celiac Disease (2)
Cell therapy (824)
Cervical cancer (40)
Clinical research (73612)
Collaboration (1942)
Company closure (4)
Compensation (1242)
Complete response letters (80)
COVID-19 (2947)
CRISPR (108)
C-suite (956)
Cystic fibrosis (155)
Data (6707)
Decentralized trials (2)
Denatured (49)
Depression (158)
Diabetes (546)
Diagnostics (7057)
Digital health (51)
Diversity (13)
Diversity, equity & inclusion (48)
Drug discovery (292)
Drug pricing (224)
Drug shortages (34)
Duchenne muscular dystrophy (262)
Earnings (93149)
Editorial (67)
Employer branding (23)
Employer resources (169)
Events (123486)
Executive appointments (1047)
FDA (20770)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (25)
Funding (1618)
Gene editing (226)
Generative AI (52)
Gene therapy (690)
GLP-1 (1125)
Government (5139)
Grass and pollen (8)
Guidances (386)
Healthcare (20020)
HIV (74)
Huntington's disease (56)
IgA nephropathy (88)
Immunology and inflammation (296)
Immuno-oncology (73)
Indications (137)
Infectious disease (3253)
Inflammatory bowel disease (215)
Inflation Reduction Act (16)
Influenza (129)
Intellectual property (268)
Interviews (566)
IPO (17208)
IRA (60)
Job creations (4291)
Job search strategy (2130)
JPM (70)
Kidney cancer (19)
Labor market (90)
Layoffs (619)
Leadership (44)
Legal (8968)
Liver cancer (100)
Longevity (21)
Lung cancer (708)
Lymphoma (395)
Machine learning (48)
Management (65)
Manufacturing (903)
MASH (180)
Medical device (14420)
Medtech (14486)
Mergers & acquisitions (21580)
Metabolic disorders (1444)
mRNA (192)
Multiple sclerosis (178)
NASH (23)
Neurodegenerative disease (369)
Neuropsychiatric disorders (107)
Neuroscience (3170)
Neurotech (1)
NextGen: Class of 2026 (7063)
Non-profit (4866)
Now hiring (70)
Obesity (703)
Opinion (346)
Ovarian cancer (175)
Pain (232)
Pancreatic cancer (251)
Parkinson's disease (307)
Partnered (37)
Patents (540)
Patient recruitment (556)
Peanut (64)
People (62500)
Pharmaceutical (96)
Pharmacy benefit managers (34)
Phase 1 (22829)
Phase 2 (32314)
Phase 3 (24211)
Pipeline (6266)
Policy (348)
Postmarket research (2850)
Preclinical (9722)
Press Release (70)
Prostate cancer (269)
Psychedelics (59)
Radiopharmaceuticals (307)
Rare diseases (1007)
Real estate (6554)
Recruiting (78)
Regulatory (26818)
Reports (55)
Research institute (2627)
Resumes & cover letters (502)
Rett syndrome (31)
RNA editing (19)
RSV (85)
Schizophrenia (164)
Series A (275)
Series B (204)
Service/supplier (11)
Sickle cell disease (107)
Special edition (29)
Spinal muscular atrophy (173)
Sponsored (47)
Startups (3994)
State (2)
Stomach cancer (21)
Supply chain (119)
Tariffs (99)
The Weekly (110)
Vaccines (1146)
Venture capital (99)
Weight loss (470)
Women's health (105)
Worklife (22)
Date
Today (195)
Last 7 days (764)
Last 30 days (3073)
Last 365 days (31359)
2026 (6011)
2025 (31508)
2024 (36570)
2023 (41480)
2022 (52732)
2021 (57397)
2020 (56245)
2019 (49303)
2018 (37406)
2017 (34541)
2016 (34356)
2015 (40167)
2014 (34155)
2013 (29372)
2012 (31498)
2011 (32166)
2010 (30450)
Location
Africa (959)
Alabama (88)
Alaska (7)
Arizona (336)
Arkansas (15)
Asia (44575)
Australia (7331)
California (11997)
Canada (3455)
China (1208)
Colorado (508)
Connecticut (518)
Delaware (353)
Europe (97741)
Florida (1819)
Georgia (390)
Hawaii (3)
Idaho (63)
Illinois (951)
India (79)
Indiana (568)
Iowa (22)
Japan (470)
Kansas (131)
Kentucky (47)
Louisiana (35)
Maine (82)
Maryland (1479)
Massachusetts (8713)
Michigan (345)
Minnesota (672)
Mississippi (6)
Missouri (134)
Montana (34)
Nebraska (29)
Nevada (133)
New Hampshire (85)
New Jersey (3184)
New Mexico (31)
New York (3172)
North Carolina (1576)
North Dakota (9)
Northern California (5882)
Ohio (363)
Oklahoma (22)
Oregon (47)
Pennsylvania (2413)
Puerto Rico (24)
Rhode Island (49)
South America (1340)
South Carolina (71)
South Dakota (1)
Southern California (4687)
Tennessee (192)
Texas (1862)
United States (42830)
Utah (362)
Vermont (1)
Virginia (294)
Washington D.C. (83)
Washington State (973)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
775,219 Results for "kinetix pharmaceuticals inc merged with amgen see amgen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Amgen Will Not Heed FDA Request To Withdraw Rare Disease Drug Tavneos
After review, Amgen is certain that Tavneos is effective and has a favorable benefit-risk profile. The company informed the FDA on January 28 that they would not pull the drug.
February 4, 2026
·
2 min read
·
Annalee Armstrong
Manufacturing
How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot
Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche planning to manufacture GLP-1 therapies there to compete in the growing market.
March 3, 2026
·
4 min read
·
Nick Paul Taylor
Earnings
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
February 4, 2026
·
2 min read
·
Tristan Manalac
Regulatory
FDA Action Alert: BMS, GSK, Amgen and More
The FDA’s docket in December includes decisions for two big biologic franchises: BMS’s Breyanzi and Amgen’s Uplizna.
December 1, 2025
·
5 min read
·
Tristan Manalac
Autoimmune disease
Amgen Ends Autoimmune Alliance With Kyowa Kirin Amid Safety, Efficacy Questions
A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data “came in at the lower end of efficacy and expectations.”
February 2, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease
While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set by Amgen’s B cell depleter Uplizna, approved by the FDA for IgG4-related disease last April.
January 6, 2026
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial
The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the management of cardiometabolic risk for patients” by 2030.
November 10, 2025
·
4 min read
·
Heather McKenzie
Obesity
Beyond MariTide: Amgen Makes Portfolio Play Amid Scrutiny of Obesity Prospect
Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech into the future.
September 10, 2025
·
5 min read
·
Nick Paul Taylor
Earnings
Amid Obesity Bidding War, Amgen Believes It Can Stand Out in Crowded Space
Amgen remains confident in its obesity asset MariTide, for which it has launched a broad Phase III program.
November 5, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
As Amgen and Lilly Recommit, Puerto Rico Seeks To Regain Manufacturing Momentum
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
February 3, 2026
·
4 min read
·
Nick Paul Taylor
1 of 77,522
Next
